On February 23, Announcement stated that the companys holding subsidiary Coronbuta will use the biomargen with its own intellectual property rights in May 2022 Project that is the "SKB264 Project" (Trop2ADC) for the exclusive permission to Merck Sharp & Amp; Dohme LLC.Research, development, manufacturing and commercialization.The project MSD is called the "MK2870 project".
As of the date of this announcement, MSD has announced the launch of SKB264/MK2870 single medicine for non-scale , the single medicine targets the endometrium cancer after platinum chemotherapy and immunotherapy, and the combined Paborizumabs three global phase III of the world with more than 50%metastatic non-small cell lung cancer in PD-L1Clinical Trials.In accordance with the agreement between Correnbo and MSD and MSD in writing, the global clinical launch of non -small cell lung cancer and uterine endometrial cancer has been paid by the global phase III clinical launch, with a total amount of 75 million US dollars.Columbia Botai has received part of the amount, and the remaining funds will be received in the near future.
(Shenzhen Stock Exchange)
(Edit: Zhou Tong)
